A Health Authority was requested to fund immune tolerance induction for a young haemophiliac at a potential cost of up to £2 million over a year. The decision-making process adopted included an external review of the case, literature review to establish the evidence base for treatment, and extensive discussions with the clinicians involved. The Health Authority agreed to fund treatment, but with continuous review of the case and explicit criteria for abandoning treatment if it was not working. After 11 months these criteria were met, and the treatment was abandoned. The decisionmaking process and ethical issues involved in deciding whether or not to fund extremely high cost treatment for an individual patient are discussed. Cases such as this present a stark contrast between rights-based and utilitarian ethical approaches. Primary Care Trusts (PCTs) are more vulnerable (because of their smaller populations and budgets) than Health Authorities were to the financial destabilization that high-cost cases can cause. PCTs are advised to make arrangements to enter risk-sharing arrangements to spread the cost of such high-cost treatments.
Introduction
Requests to fund very high cost treatment for a single individual present Primary Care Trusts (PCTs) (and in the past, Health Authorities) with peculiar difficulties. The general requirement to provide effective health care for the population for which they are responsible is brought into conflict with considerations of opportunity cost and the requirement to achieve financial balance. The identification of a particular individual, for whom funding for treatment is being requested, may add an explicit emotional element to decision making that is absent when considering funding service developments or other broader treatment programmes. Decisions need to be made within the context of clinical and corporate governance, as they apply to commissioning organizations within the National Health Service. There is also the ever-present possibility of scrutiny by media or politicians. It is therefore particularly important that the process for handling of these requests should be open, fair, consistent and robust to scrutiny.
The treatment of patients with haemophilia who develop inhibitors to Factor VIII (FVIII) is problematic and expensive. [1] [2] [3] [4] This paper describes the way in which a commissioning Health Authority managed a request to fund extremely high cost treatment for a single patient.
Case history
In February 1999 the Health Authority was contacted by the consultant haematologist responsible for the care of a nineyear-old with haemophilia A who had had inhibitors (antibodies) since the age of three. Inhibitor development is a recognized complication of treatment of haemophilia with FVIII. 5 The patient responds to FVIII as a foreign protein, and so produces antibodies. These then react with any FVIII that is administered, thus rendering it ineffective as a treatment. This prevents both prophylaxis against bleeding as well as the treatment with FVIII of any bleeding episodes that do occur. Alternative means to treat active bleeding do exist, but are all less satisfactory than treatment with FVIII. The lack of any prophylaxis renders the patient vulnerable to repeated bleeds, of which the most significant would be haemarthroses (leading eventually to arthropathy) and intracerebral bleeds.
Once they are established, the only recognized means to abolish inhibitors is through immune tolerance induction (ITI). 6, 7 This involves administering large quantities of FVIII, which eventually leads to the ablation of the inhibitor. When this is achieved, immune tolerance appears in most cases to be long lasting, and 'normal' treatment with FVIII can be resumed.
For debate
Very high cost treatment for a single individual -a case report
The consultant haematologist thought that ITI ought to be considered for this patient. He was keen that every effort should be made to abolish the inhibitor before the patient reached puberty, with the associated increased risk of bleeding and difficulties in sustaining a demanding treatment regime. Further, as his weight increased with age, the dose and hence cost of treatment would increase. Abolition of inhibitor and restoration of a prophylactic FVIII regime should be undertaken as soon as possible to minimize the risk of permanent arthropathy. The consultant requested that the Health Authority should make funding available for a 'high-dose' ITI regime. Because the dosage is calculated on a per weight basis, and the boy already weighed 60 kg, this would cost £1.97 million pounds over 12 months, although it would be reviewed at the 6 month point. The consultant pointed out that the alternative would involve treating any bleeding episodes with recombinant Factor VIIa, which costs £2700 per dose, with multiple doses being required for any one episode.
A literature search was undertaken by a Consultant in Public Health Medicine from the Health Authority to establish the evidence base for ITI and investigate alternative approaches. This revealed that although there were no controlled trials of this treatment, case series reported success in abolishing inhibitors in up to 90 per cent of patients 7, 8 (and an understanding that without treatment, the inhibitor persists). No persuasive evidence for any alternative approach to treatment was found. The Consultant discussed the case with the Haematologist, both over the phone and in person, and it was agreed that, before any decision on funding was made, an independent clinical review of the patient should be commissioned by the Health Authority.
In April 1999 the external review was undertaken by a Haematologist from another centre in the Region. He agreed that high-dose ITI ought to be considered. In his view, the existing FVIII regime was not working. It had amounted in effect to a 'low-dose' immune tolerance regime. The likelihood of highdose ITI being effective was estimated at approximately one in three, with treatment lasting 12-18 months. Alternative approaches to immune tolerance were dismissed. If the inhibitor were not abolished, no prophylactic treatment would be possible, and bleeds would have to be treated with FVIIa, at a cost of approximately £10 000 per bleed. Three bleeding episodes had occurred in the previous 3 months.
The case was discussed with the patient's general practitioner (GP), who was also by chance the chairman of the GP locality commissioning group. His view was that treatment should be funded if it stood any chance of being effective. It was also discussed with the Regional Director of Public Health (DPH), and the possibility of additional funding being made available to the Health Authority was explored. Although it was not possible for additional funds to be made available for the treatment of the specific patient, the exceptional circumstances were taken into account by the Regional Office when considering the yearend financial position of the Health Authority. The Regional DPH stated that, in his view, there is a public expectation that treatments such as these will be funded unless they are of no benefit. It was agreed by all that the final decision as to whether or not the treatment would be funded would be one for the Health Authority Board to take.
The case was discussed by the Health Authority Board in May 1999. After a vote (in itself an unusual occurrence), it was agreed that funding for up to 18 months treatment would be made available.
Following this, further discussions were held with the Haematologist. Because published reports suggested that the likelihood of success was greater with lower levels of inhibitor at the start of treatment, 8, 9 it was decided that FVIII treatment should cease altogether (and FVIIa be used to treat bleeds) to allow the inhibitor level to fall before starting ITI. It was also agreed that, because of the enormous cost of treatment, it would be important to monitor it closely, and withdraw treatment promptly if it became clear that it was not being effective.
To this end clear criteria were agreed between the Consultant in Public Health Medicine and the Haematologist for abandoning treatment, and shared with the boy and his parents. These were based on the monitoring criteria in a proposed trial comparing low-dose and high-dose ITI (C. R. Hay and International ITI study group, personal communication). Inhibitor levels would be monitored on a monthly basis, and if, starting after 9 months treatment, the level were not at least 20 per cent less than that obtaining 6 months earlier, for two successive months, the treatment would be deemed ineffective and abandoned. The patient would also receive further intensive dietary advice and be encouraged to lose weight.
The inhibitor level fell on withdrawal of FVIII treatment, as anticipated, and ITI was started in December 2000. Following the immediate (expected) anamnestic rise in inhibitor level there was then a steady fall. However, after the fourth month of treatment the fall ceased, and in the seventh month there was a significant rise in titre, associated with a change in treatment from recombinant to plasma-derived FVIII (because of world-wide problems with the supply of recombinant FVIII) and an infection in the indwelling central venous catheter being used to administer treatment. Although it fell again subsequently, it did not fall as low as the level that had been observed in the third to fifth months. The criteria for continuing treatment were therefore not met after nine and 10 months. However, because of the change of product and line infection, it was decided to continue treatment for a further month to see whether downward progress in inhibitor titre would be resumed. After 11 months there was a further slight rise in titre, leading to the conclusion that the treatment was not working. A clinical decision was therefore made that it should cease.
Discussion
Individual very high cost cases are inevitably difficult for commissioners to handle, for a number of reasons. Commissioners will want to have access to the best evidence on effectiveness of the proposed treatment, but inevitably the treatments for which funding is being requested are extremely infrequent, so it is unlikely that there will be randomized controlled trials on which decision making can be based. The best quality evidence available is likely to be case reports or case series, which are themselves likely to report cases that differ in some significant details from the case under consideration.
These cases also present the conflict between rights-based and utilitarian approaches to the ethics of resource allocation in a rarified form. On the one hand, an identified individual is in need of treatment to prevent or ameliorate extreme disability, or to prevent death. That he or she has a right to such a treatment, particularly within a socialized system of health care such as the National Health Service, might be seen as self evident. On the other hand, the resources that this treatment would consume could undoubtedly be used to purchase significant health gain (both for individual patients, but more particularly when aggregated), so that the greatest good for the greatest number, the utilitarian goal, will be achieved by turning down the request and using the resources in other ways. The conflict between these ethical approaches cannot be bridged. In general, clinicians tend to favour a rights-based view of medical ethics, whereas public health physicians tend to be more utilitarian.
This conflict, between rights-based and utilitarian approaches, may well play itself out in different ways in the future as the responsibility for such decisions shifts from Health Authorities to PCTs. The structure of PCT Boards and Professional Executive Committees includes much greater clinician input than Health Authority Boards. This may lead them to take a more rights-based, rather than utilitarian, view.
The Health Authority, in deciding whether or not to fund this case, was able to refer to its stated 'Values and Principles' (see Fig. 1 ). However, these do not unequivocally lead to a decision one way or the other. The second, fifth and eighth principle could be taken to support funding of the case, whereas the third, sixth and eleventh could be taken to do the opposite! Subsequently, more explicit criteria have been developed for use in considering 'exceptional cases' (see Fig. 2 ). However, these too are not prescriptive, as basing a decision on an assessment of need may run counter to evidence of cost-effectiveness.
A number of different wrong decisions can be made. Not funding treatment that would have benefited the patient could be the wrong decision if in the longer term it would have been cost effective, if the alternative uses of the resources do not purchase as much 'health gain', or if the decision is made without due consideration. However, funding treatment could also be the wrong decision if it turns out not to be effective. Funding treatment that is effective will have significant opportunity costs. Funding treatment that turns out not to be effective compounds this, in that even the hoped for health gain is not achieved. Some damage limitation can be effected in this eventuality by ensuring that clear criteria are established for monitoring and withdrawing the treatment if it is clear that it is not being effective, as was done in this case. Against this background, there is a clear responsibility on commissioners (to date, Health Authorities, from now, PCTs) to make effective treatment available. This includes individual high-cost treatments, although affordability always has to be considered, and there is a requirement for commissioning organizations to 'balance the books'. Patients do not have a right to treatment, irrespective of cost. At the same time, decisions made by commissioners, as much as other organizations within the Health Service, are increasingly under public scrutiny, and are always open to challenge through judicial review. In this instance, this case prompted a whole system review of decision making in the commissioning process, encompassing service investment issues as well as individual patient requests.
If these competing pressures are to be resolved, commissioners must consider, and be seen to consider, each such case on We are here to promote and improve the health and wellbeing of our people and reduce health inequalities.
Our values and principles underpin everything we do. These are:
Listening to, involving and acting on the views of our staff and our people;
Working strategically and collaboratively with our partners; Supporting community developments for health;
Developing effective services;
Promoting clinical excellence;
Taking a holistic approach to service delivery; Openness;
Ensuring services are provided on the basis of need;
Having a clearly understood process for prioritization;
Ensuring effective use of resources;
Promoting anti-discriminatory practice and equal opportunities; Implementing national policy sensitively to local need;
As an employer, commit to excellent working practices. Give due consideration to claims of the patient and accord due weight to these claims versus other competing claims;
Take acccount of all epidemiological data including clinical and cost-effectiveness data where available; Not take into account any irrelevant matters;
Arrive at a decision which cannot be legitimately described as irrational or absurd;
Be taken in utmost good faith.' Figure 2 Extract from the decision-making framework for exceptional cases.
its individual merits. This necessitates close co-operation with the clinicians responsible for the patient. However, they may (appropriately) have strong feelings about the case, and cannot be expected to weigh the needs of the individual against the needs of the many (nor is it likely that they would want to). It is therefore likely to be helpful to obtain an independent clinical opinion, notwithstanding the fact that in a small specialty with an unusual case it may be difficult to find a truly 'independent' outside expert. Those handling the case may also find it helpful to discuss it with anyone who has had experience in similar cases in other commissioning organizations. Clear records must be kept of all aspects of the case, including verbal communications, lest the decision that is eventually made be subject to legal or other challenge. Furthermore, although all concerned will doubtless prefer to keep it out of the media, the possibility that it might become public should be considered, and an appropriate communication strategy developed.
There is merit in considering risk-sharing arrangements for high-cost treatments (particularly for PCTs, which on the whole have smaller budgets than Health Authorities, and are thus more vulnerable). In the past, Health Authorities have on occasion been allowed latitude in their year-end financial position to take account of unexpected expenditures such as this, which has acted as a form of risk sharing over time, rather than between organizations. Clearly, any such arrangements between organizations must be established in advance, as there will be little enthusiasm among potential partners for joining at the time when a high-cost case has to be considered. However, any arrangement of this nature is likely to be confined to clearly defined clinical areas, and there will always be the possibility of a high-cost case presenting in an area not covered by them. The final decision as to whether such treatment will be funded must in the end fall on the organization responsible for the commissioning budget, using whatever structures it has in place for such decision making.
Conclusion
Very high cost individual treatments present commissioners with difficult decisions. However, a reasoned approach is possible, which will help to ensure that a defensible decision is made that balances the need of the individual patient with the wider responsibilities of the commissioning organisation. The financial difficulties that such cases present can be mitigated by risk-sharing arrangements, which PCTs should seriously consider, but the fundamental dichotomy between the rights-based and utilitarian approaches to the ethical issue cannot be fudged, and should be explicitly addressed in any statement of values or decision-making criteria that commissioners adopt.
